Trillium Therapeutics (Trillium Therapeutics) Price-to-Tangible-Book : 8.54 (As of May. 09, 2024)

View and export this data going back to 2009. Start your Free Trial

What is Trillium Therapeutics Price-to-Tangible-Book?

As of today (2024-05-09), Trillium Therapeutics's share price is $18.44. Trillium Therapeutics's Tangible Book per Share of Sep. 2021 for the quarter that ended in Sep. 2021 was $2.16. Hence, Trillium Therapeutics's Price to Tangible Book Ratio of today is 8.54.

The historical rank and industry rank for Trillium Therapeutics's Price-to-Tangible-Book or its related term are showing as below:

TRIL' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.74 Med: 4.24 Max: 34.35
Current: 8.42

During the past 13 years, Trillium Therapeutics's highest Price to Tangible Book Ratio was 34.35. The lowest was 0.74. And the median was 4.24.

TRIL's Price-to-Tangible-Book is not ranked
in the Biotechnology industry.
Industry Median: 2.735 vs TRIL: 8.42

A closely related ratio is called PB Ratio. As of today, Trillium Therapeutics's share price is $18.44. Trillium Therapeutics's Book Value per Sharefor the quarter that ended in Sep. 2021 was $2.17. Hence, Trillium Therapeutics's P/B Ratio of today is 8.51.

Trillium Therapeutics Price-to-Tangible-Book Historical Data

The historical data trend for Trillium Therapeutics's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Trillium Therapeutics Price-to-Tangible-Book Chart

Trillium Therapeutics Annual Data

Trend

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Price-to-Tangible-Book

Get a 7-Day Free Trial

4.20

6.99

5.77

Trillium Therapeutics Quarterly Data
	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21
Price-to-Tangible-Book	Get a 7-Day Free Trial															8.65	5.77	4.31	4.18	8.13

Competitive Comparison of Trillium Therapeutics's Price-to-Tangible-Book

For the Biotechnology subindustry, Trillium Therapeutics's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Trillium Therapeutics's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Trillium Therapeutics's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Trillium Therapeutics's Price-to-Tangible-Book falls into.

Trillium Therapeutics Price-to-Tangible-Book Calculation

Trillium Therapeutics's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book	=	Share Price	/	Tangible Book per Share (Q: Sep. 2021 )
	=	18.44	/	2.159
	=	8.54

It can also be calculated from the numbers for the whole company:

Price to Tangible Book	=	Market Cap	/	Tangible Equity
	=	Market Cap	/	(Total Stockholders Equity	-	Preferred Stock	-	Intangible Assets)

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.

Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.

Trillium Therapeutics Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Trillium Therapeutics's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.

Trillium Therapeutics (Trillium Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Trillium Therapeutics Inc (NAS:TRIL) » Definitions » Price-to-Tangible-Book

Comparable Companies

Traded in Other Exchanges

N/A

Address

100 CambridgePark Drive, Suite 510, Cambridge, MA, USA, 02140

Website

https://www.trilliumtherapeutics.com

Trillium Therapeutics Inc is a clinical-stage immuno-oncology company that is engaged in developing therapies for the treatment of cancer. It has two clinical programs, TTI-621 and TTI-622, that target CD47. The company operates in the United States and Canada.